-

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November:

  • Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am (EST)
  • Jefferies Global Healthcare Conference (London) on Tuesday, November 18, 2025 at 11:00 am (GMT)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Contacts

Incyte Contacts
Media
media@incyte.com

Investors
ir@incyte.com

Industry:

Incyte

NASDAQ:INCY
Release Versions
English

Contacts

Incyte Contacts
Media
media@incyte.com

Investors
ir@incyte.com

More News From Incyte

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or Refractory DLBCL...

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

WILMINGTON, Del.--(BUSINESS WIRE)--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET...

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

WILMINGTON, Del.--(BUSINESS WIRE)--Results from Incyte’s frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survival...
Back to Newsroom